查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1243267

高雪氏症治療藥的全球市場

Gaucher Disease Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

高雪氏症治療藥的全球市場在2030年前將達到25億美元

在COVID-19後改變的商務環境中，2022年19億美元的高雪氏症治療藥的全球市場，在2030年前將達到25億美元，在2022年～2030年預計將以年複合成長率3.8％的速度成長率。本報告所分析之市場區隔之一的酵素補充療法，年複合成長率將記錄3.4％，到分析期間結束時將達到15億美元。考慮疫情後的復甦趨勢，基材降低療法領域今後8年的年複合成長率將修正為4.3％。

美國市場估算為5億6,470萬美元，中國則以預測年複合成長率3.5％的速度成長

美國的高雪氏症治療藥市場在2022年估算為5億6,470萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為3.5％，在2030年前將達到4億4,850萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以3.5％和3.2％的速度成長。在歐洲市場中，德國以年複合成長率3.8％成長。

調查對像企業範例

  • Abbott
  • Actelion Pharmaceuticals Ltd.(Johnson & Johnson)
  • Anthera Pharmaceuticals, Inc.
  • Aptalis Pharma
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Genzyme Corporation
  • GlaxoSmithKline(GSK)
  • JCR Pharmaceuticals Co Ltd
  • Lixte Biotechnology Holdings Inc
  • MedPro Rx
  • Merck Serono
  • Orphazyme ApS
  • Pfizer Inc.
  • Pharming Group NV
  • Shire Human Genetic Therapies, Inc.
  • Zymenex A/S

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP12147

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Gaucher Disease Treatment Market to Reach $2.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Gaucher Disease Treatment estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$2.5 Billion by 2030, growing at aCAGR of 3.8% over the period 2022-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is projected to record 3.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Substrate Reduction Therapy segment is readjusted to a revised 4.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $564.7 Million, While China is Forecast to Grow at 3.5% CAGR

The Gaucher Disease Treatment market in the U.S. is estimated at US$564.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$448.5 Million by the year 2030 trailing a CAGR of 3.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 42 Featured) -

  • Abbott
  • Actelion Pharmaceuticals Ltd. (Johnson & Johnson)
  • Anthera Pharmaceuticals, Inc.
  • Aptalis Pharma
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Genzyme Corporation
  • GlaxoSmithKline (GSK)
  • JCR Pharmaceuticals Co Ltd
  • Lixte Biotechnology Holdings Inc
  • MedPro Rx
  • Merck Serono
  • Orphazyme ApS
  • Pfizer Inc.
  • Pharming Group NV
  • Shire Human Genetic Therapies, Inc.
  • Zymenex A/S

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Gaucher Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gaucher Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Gaucher Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Substrate Reduction Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Non-neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Non-neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Non-neuronopathic Gaucher disease Clients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Neuronopathic Gaucher disease Clients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Gaucher Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • JAPAN
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • CHINA
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: China 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: China 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • EUROPE
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Gaucher Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Gaucher Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • FRANCE
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: France 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: France 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • GERMANY
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030

IV. COMPETITION